Aiosyn Announces The Formation Of A Scientific Advisory Board To Guide The Continued Development Of Its Kidney AI Suite
admin@pathologynews.com2023-10-18T08:37:44+00:00Aiosyn, a medical software company specializing in AI-powered pathology solutions for cancer and kidney diseases, has announced the formation of its Scientific Advisory Board. The advisory board is being formed to provide scientific and medical guidance for the continued development of Aiosyn’s Kidney AI Suite. Within this platform, Aiosyn is developing AI-powered algorithms that provide objective quantification of kidney lesion scores, with the aim to ultimately improve the efficiency and reproducibility of results.










